CD19 and B-cell non-Hodgkin lymphoma: Chimeric antigen receptor (CAR) T cell therapy, whereby autologous T cells are isolated and engineered to specifically target antigens on the malignant cell surface (e.g. CD19 on B cell lymphoma) is established in the treatment of B cell lymphomas including diffuse large B cell lymphoma (DLBCL), follicular lymphoma and mantle cell lymphoma (8–13).